Company profile: Ambit Biosciences
1.1 - Company Overview
Company description
- Provider of small molecule kinase inhibitor discovery and development for cancer, autoimmune, and inflammatory diseases, including quizartinib (AC220), a potent, selective FLT3 inhibitor for AML, AC410 (JAK2 inhibitor), and AC708 (CSF1R inhibitor), supported by the KinomeScan platform for screening kinase inhibitors.
Products and services
- Quizartinib: A highly selective, orally bioavailable FLT3 kinase inhibitor engineered for acute myeloid leukemia, targeting FLT3-ITD mutations with potent activity and oral dosing convenience
- KinomeScan: A screening-focused technology platform used to profile kinase inhibitors, accelerating discovery and development of targeted therapies by assessing inhibitor selectivity across kinase targets
- AC410: A selective JAK2 small molecule inhibitor with oral administration, developed for autoimmune and inflammatory diseases to inhibit JAK2-driven signaling implicated in these conditions
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Ambit Biosciences
Endocare
HQ: United States
Website
- Description: Provider of medical devices and related consumables for cryoablation, developing, manufacturing, and distributing these products.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Endocare company profile →
Oncocyte
HQ: United States
Website
- Description: Provider of blood-based and gene expression tests and biopharma services: DetermaCNI detects cancer progression early via cell-free DNA instability; DetermaIO assesses the tumor immune microenvironment to identify immunotherapy benefit; VitaGraft Kidney/Liver quantify donor-derived cell-free DNA to monitor transplant health and detect rejection; GraftAssure uses droplet digital PCR; and tissue- and blood-based biomarker-driven clinical trial support.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oncocyte company profile →
hC Bioscience
HQ: United States
Website
- Description: Provider of engineered tRNA-based protein editing platforms and therapeutics, including PTCX (Patch) to suppress nonsense mutations in mRNA and restore full-length protein, SWTX (Switch) to mark disease-causing proteins for destruction, and engineered tRNA therapies to correct multiple mutant proteins across various disease indications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full hC Bioscience company profile →
Veran Medical
HQ: United States
Website
- Description: Provider of image-guided medical devices and a suite of products that help physicians diagnose disease and deliver therapies, including standards for minimally invasive delivery of interventional oncology therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Veran Medical company profile →
Adaptimmune
HQ: United Kingdom
Website
- Description: Provider of T-cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases, including afami-cel, a single-dose T-cell therapy targeting cancer, and lete-cel, a single-dose T-cell therapy in development for treating solid tumors.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Adaptimmune company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Ambit Biosciences
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Ambit Biosciences
2.2 - Growth funds investing in similar companies to Ambit Biosciences
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Ambit Biosciences
4.2 - Public trading comparable groups for Ambit Biosciences
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →